Fierce Pharma

JUNE 14, 2024

With a deal worth up to $1.3 billion, Takeda could get its hands on a “potentially best-in-class” third-generation BCR-ABL tyrosine kinase inhibitor (TKI) that could rival Novartis' Scemblix.< | In deal potentially worth up to $1.3 billion, Takeda has gained an option to license Ascentage's third-generation tyrosine kinase inhibitor, which could go up against Novartis' Scemblix in chronic myeloid leukemia.

308

308

MedCity News

JUNE 14, 2024

Better Health’s $14 million in funding included investments from Healthworx, the University of Miami Health System and Mosaic General Partnership. The post Better Health Raises $14M To Reach More Patients with Chronic Conditions appeared first on MedCity News.

Patients 105

Patients 105

Fierce Pharma

JUNE 14, 2024

Six months after Vertex earned a historic FDA approval for sickle cell d | Six months after Vertex earned a historic FDA approval for sickle cell disease (SCD) gene therapy Casgevy (exa-cel), long-term data is beginning to show the consistent efficacy and durability of the treatment, which is the first ever to be developed using CRISPR gene editing technology.

FDA 254

FDA 254

MedCity News

JUNE 14, 2024

This week, Wheel rolled out a new AI-powered platform designed to provide patients with more holistic and seamless virtual care journeys. The platform, called Horizon, aims to help the startup’s customers rapidly scale virtual care programs to meet growing patient demand. The post Wheel’s New AI Platform Seeks to Power the New Era of Virtual Care appeared first on MedCity News.

Patients 104

Patients 104

Advertisement

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

Sales Management

Fierce Pharma

JUNE 14, 2024

Each June, the American Society of Clinical Oncology (ASCO) hosts a conference that gathers physicians, researchers and the cancer community to share their latest research on treatments, technologi | In this week's episode of "The Top Line," journalists from Fierce Biotech and Fierce Pharma discuss the most talked-about data drops at ASCO and share on-the-ground details, including their experience with Gilead’s virtual reality Trodelvy ride.

Physicians 208

Physicians Pharma 208

ALULA

JUNE 14, 2024

June is National Men's Health Month and a call to prioritize men's mental and physical well-being, the bedrock for success in all aspects of life. Leaders know that our health lays the foundation for our career achievements, team relationships, and overall resilience. However, one piece of men's health puzzle is often missing in our conversations.

98

98

European Pharmaceutical Review

JUNE 14, 2024

AbbVie and FutureGen Biopharmaceutical (Beijing) Co., Ltd. have made a license agreement, whereby AbbVie will develop, manufacture and commercialise a next generation TL1A antibody for inflammatory bowel disease (IBD). FG-M701 is a fully human monoclonal antibody targeting TL1A. This target plays a role in inflammatory autoimmune diseases. While AbbVie is set to advance the monoclonal antibody through development and beyond, the treatment is currently in preclinical development.

Manufacturing 98

Manufacturing Pharma Pharmaceutical Patients 98

Fierce Pharma

JUNE 14, 2024

A Bristol Myers Squibb drug has got an FDA approval to treat tumors with a specific biomarker regardless of their locations in the body. | A Bristol Myers Squibb drug has got an FDA approval to treat tumors with a specific biomarker regardless of their locations in the body, and it's facing two competitors.

FDA 140

FDA 140

MedCity News

JUNE 14, 2024

Cutting-edge technology empowers developers to proactively detect and mitigate issues before they cause problems, reducing recalls and fostering trust in the industry. The post From Recalls to Reliability: Tools to Ensure Software Safety in MedTech appeared first on MedCity News.

Safety 102

Safety Patients Medical 102

Pharmaceutical Technology

JUNE 14, 2024

If exercised, the option would allow Takeda to license the TKI olverembatinib outside China, Hong Kong, Macau, Taiwan and Russia.

105

105

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patients

MedCity News

JUNE 14, 2024

Bristol Myers Squibb drug Augtyro now has a tumor-agnostic approval permitting the drug to be used to treat all solid tumors positive for NTRK gene fusions. Augtyro came from BMS’s $4.1 billion acquisition of Turning Point Therapeutics. The post New FDA Nod Brings Bristol Myers Squibb Cancer Drug to a Wider Range of Solid Tumors appeared first on MedCity News.

FDA 101

FDA Biopharma Pharma 101

Pharmaceutical Technology

JUNE 14, 2024

AbbVie has made a licence agreement with FutureGen Biopharmaceutical for developing FG-M701 for inflammatory bowel disease (IBD).

105

105

MedCity News

JUNE 14, 2024

Solving this problem will require a multi-pronged approach that includes recruitment, technology, and help from lawmakers. The post Addressing Healthcare Workforce Shortages Beyond Band-Aids appeared first on MedCity News.

Healthcare 95

Healthcare Healthcare Recruitment Physicians 95

Pharmaceutical Technology

JUNE 14, 2024

England’s NHS has reported an 18% increase in the number of people with non-diabetic hyperglycaemia, also known as pre-diabetes.

98

98

Advertisement

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

Sales

PharmaTimes

JUNE 14, 2024

NSCLC accounts for around 85% of all lung cancer cases, particularly in non-smoking patients

Patients 109

Patients 109

PharmaTech

JUNE 14, 2024

Novel approaches against chronic inflammation could potentially prevent certain inflammatory diseases and neurological conditions.

69

69

PharmaTimes

JUNE 14, 2024

The installation will double the capacity of cancer genomic testing using robotic automation

97

97

pharmaphorum

JUNE 14, 2024

Radiopharma firm Telix abandons Nasdaq listing plans Phil.

111

111

Advertisement

PharmaTech

JUNE 14, 2024

John Bertagnolli, vice-president of Commercial Operations at Selkirk Pharma, discusses considerations when building and scaling up pharmaceutical facilities, including contamination control and aseptic processing challenges.

Pharmaceutical 52

Pharmaceutical Pharma 52

PharmExec

JUNE 14, 2024

Data presented at the European Hematology Association Congress indicated that patients with chronic lymphocytic leukemia treated with Imbrivica had a significantly longer median progression-free survival compared to patients treated with chlorambucil.

Safety 52

Safety Patients 52

Pharmaceutical Commerce

JUNE 14, 2024

The contract manufacturer financially committed over $107 million into the facility, which can reportedly handle large-scale manufacturing of active ingredients based on messenger ribonucleic acid.

Manufacturing 52

Manufacturing 52

PharmExec

JUNE 14, 2024

Data presented at the European Hematology Association Congress indicated that patients with chronic lymphocytic leukemia treated with Imbrivica had a significantly longer median progression-free survival compared to patients treated with chlorambucil.

Safety 52

Safety Patients 52

Advertisement

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

Sales

Pharmaceutical Commerce

JUNE 14, 2024

In this Pharmaceutical Commerce video interview, Blake Powers, CEO of Medigi, discusses his first byline with the publication, along with why the industry may be stuck in its ways in certain aspects.

Pharmaceutical 52

Pharmaceutical 52

PharmExec

JUNE 14, 2024

Approval for Augtyro was based on results from the Phase I/II TRIDENT-1 trial, which demonstrated significant response rates in both tyrosine kinase inhibitor (TKI) naïve and TKI-pretreated patients.

FDA 52

FDA Patients 52

LEVO Health

JUNE 14, 2024

The healthcare industry – along with the rest of the modern world – is witnessing a transformative shift with the integration of artificial intelligence (AI), reshaping the way providers interact with and care for patients. AI’s ability to analyze data, recognize patterns, and automate communications is revolutionizing patient care by making it more personalized, efficient, and responsive.

Healthcare 52

Healthcare Healthcare Patients Healthcare Provider 52

PharmExec

JUNE 14, 2024

Highlighted by notable company and product maneuvering at the top and the continued dramatic growth of therapeutic settings such as GLP-1s, Pharm Exec’s latest listing of the top global biopharma sales producers is proof-positive of an industry in transition.

Biopharma 52

Biopharma Sales 52

Advertisement

Distribution

Scott Burrows

JUNE 14, 2024

Back in the early 90’s, during my tenure as a financial advisor at Northwestern Mutual Life, I had the privilege of attending their annual meeting in Milwaukee, WI. The keynote speaker at that event was Captain Charlie Plumb. His inspirational story of being a prisoner of war for 6 years, and having the strength to build resilience, captivated thousands of us in the audience and earned him a standing ovation.

52

52

PharmExec

JUNE 14, 2024

In this part of his Pharmaceutical Executive video interview, Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, and what needs to be done for GLP-1s to be covered.

FDA 52

FDA Pharmaceutical 52

pharmaphorum

JUNE 14, 2024

DeepWell gamifies breathing therapy for mental health Phil.

110

110

PharmExec

JUNE 14, 2024

Our June issue of Pharmaceutical Executive offers a uniquely diverse range of coverage and voices—a "sum-of-its-parts" balance that's not always easy to pull off.

Pharmaceutical 52

Pharmaceutical 52

Advertisement

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A

Sales